Stoyianni A - Search Results

1

Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary.

Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Goussia A, Stoyianni A, Sanden M, St Cyr B, Yerushalmi N, Benjamin H, Meiri E, Chajut A, Rosenwald S, Aharonov R, Spector Y. Pentheroudakis G, et al. Among authors: stoyianni a. Mol Cancer. 2013 Jun 10;12:57. doi: 10.1186/1476-4598-12-57. Mol Cancer. 2013. PMID: 23758919 Free PMC article.

2

Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study.

Stoyianni A, Pentheroudakis G, Benjamin H, Cervantes A, Ashkenazi K, Lazaridis G, Pavlidis N, Spector Y. Stoyianni A, et al. Clin Transl Oncol. 2014 Aug;16(8):725-31. doi: 10.1007/s12094-013-1139-5. Epub 2013 Nov 27. Clin Transl Oncol. 2014. PMID: 24282096

3

Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis?

Pentheroudakis G, Stoyianni A, Pavlidis N. Pentheroudakis G, et al. Among authors: stoyianni a. Cancer Treat Rev. 2011 Apr;37(2):120-6. doi: 10.1016/j.ctrv.2010.06.003. Epub 2010 Jul 31. Cancer Treat Rev. 2011. PMID: 20673701

4

Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors.

Stoyianni A, Pentheroudakis G, Pavlidis N. Stoyianni A, et al. Cancer Treat Rev. 2011 Aug;37(5):358-65. doi: 10.1016/j.ctrv.2011.03.002. Epub 2011 Apr 9. Cancer Treat Rev. 2011. PMID: 21481536 Review.

5

Incorporation of targeted agents in the management of patients with advanced gastric cancer.

Pentheroudakis G, Stoyianni A. Pentheroudakis G, et al. Among authors: stoyianni a. Curr Med Chem. 2011;18(11):1629-39. doi: 10.2174/092986711795471365. Curr Med Chem. 2011. PMID: 21428884 Review.

6

Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.

Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D, Golfinopoulos V, Cervantes A, Bobos M, Fotsis T, Bellou S, Fountzilas G, Malamou-Mitsi V, Pavlidis N. Stoyianni A, et al. Anticancer Res. 2012 Apr;32(4):1273-81. Anticancer Res. 2012. PMID: 22493359

7

Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.

Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D, Stoyianni A, Golfinopoulos V, Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N. Krikelis D, et al. Among authors: stoyianni a. Clin Exp Metastasis. 2012 Aug;29(6):603-14. doi: 10.1007/s10585-012-9474-4. Epub 2012 Apr 19. Clin Exp Metastasis. 2012. PMID: 22526456

8

Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.

Stoyianni A, Kapodistrias N, Kampletsas E, Pentheroudakis G, Pavlidis N. Stoyianni A, et al. Tumori. 2011 Mar-Apr;97(2):252-5. doi: 10.1177/030089161109700223. Tumori. 2011. PMID: 21617727

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters